Tanner Pharmaceuticals and BurnsAdler Pharmaceuticals merge
To form Tanner Pharma Group
Tanner Pharmaceuticals, a global pharma services company and BurnsAdler Pharmaceuticals, a speciality pharmaceutical company that licenses and acquires pharmaceuticals, medical devices and over-the-counter (OTC) products for commercialisation in Latin America and other international markets, have merged to form Tanner Pharma Group.
No financial details have been revealed.
The newly formed business is a portfolio company of Bourne Partners, a healthcare-focused merchant bank headquartered in Charlotte, NC in the US,that offers financial advisory, direct investment and management consulting services to life sciences partners around the world.
Tanner Pharma Group consists of three complementary divisions: Tanner Clinical Trial Sourcing (TannerCTS); Tanner Global Access Programmes (TannerGAP); and Tanner Licensing, Acquisition and Commercialisation (TannerLAC).
TannerCTS procures products for manufacturers, CROs and research centres from a broad range of sources. Additionally, the company provides clinical trial logistics and inventory management for trials conducted in the US, Europe, Mexico and Brazil.
TannerGAP serves manufacturers and providers by developing, implementing and managing Global Access Programmes in international markets.
Meanwhile, TannerLAC serves pharmaceutical, biotech and healthcare companies by maximising the commercial potential for their products in Latin America and other markets. The company's licensing and registration model is said to minimise the risk, investment and resources necessary for companies to achieve their revenue goals in non-core, international markets.
Maryori Alvarenga, Director of Sales & Operations for Tanner Pharma Group, said: 'This merger is exciting for two reasons. First, it caps off an exciting phase of growth for our companies, which combined for revenue growth of 880% over the last four years; and second, it signifies the start of the next phase of our Global Growth Strategy.'
Coinciding with the merger is the opening of Tanner Pharma Group’s London office, the company’s third international hub, which will oversee business development and operations for UK/EU opportunities within the TannerCTS and TannerGAP divisions.
